In contrast, because it was prospectively identified, crizotinib was recently approved by the US Food and Drug Administration (FDA) only for the treatment of advanced NSCLC proven to harbour an ALK gene rearrangement, an abnormality present in <5% of the NSCLC population (Kwak et al, 2010). This evidence concerns the gene ALK and non-small cell lung carcinoma.